S.Korea's CGBio exports $8 mn filler to Australia, New Zealand
Ji-Hyun Lee
Mar 24, 2023 (Gmt+09:00)
CGBio, a South Korean bio-regenerative medical company, announced on Thursday that it has signed a contract to export its hyaluronic acid (HA) filler "Aileene" to Australia and New Zealand for a total of 10.4 billion won ($8 million).
The company's business partner for the contract is Amore Aesthetics, a local company with a sales and distribution network in Oceania.
The news comes after CGBio signed an agreement on March 21 to supply fillers to China worth $360 million over three years.
"As Aileene's first foray into the Australian and New Zealand market, we will spare no effort to provide active support to ensure successful distribution in the region," said Yu Hyun-seung, CEO of CGBio.